Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 7, 1996, Pages 2638-2641

  Hoelting, Thomas ^a,d   Duh, Quan Yang ^b   Clark, Orlo H ^c   Herfarth, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; THYROID CANCER; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OCTREOTIDE; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030015186     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.7.2638     Document Type: Article

References (30)

1. Mizukami Y, Takatoshi M, Nonomura A, et al. 1990 Distant metastases in differentiated thyroid carcinoma: a clinical and pathologic study. Hum Pathol. 21:283-290.
2. Clark OH. 1982 Total thyroidectomy-the treatment of choice for patients with differentiated thyroid cancer. Ann Surg. 196:361-370.
3. Mazzaferri EL, Young RL. 1981 Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 70:511-516.
4. Lamberts SWJ, Krenning EP, Reubi JC. 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 12:450-481.
5. Stalla G, Brockmeier SJ, Renner U, et al. 1994 Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol. 130:125-131.
6. Ruszniewski P, Girard F, Benamouzig R, Mignon M, Bonfils S. 1988 Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome. Gut. 29:838-842.
7. Nemeroff CB, Walsh TJ, Bissette G. 1986 Somatostatin and behaviour preclinical and clinical studies. In: Reichlin S, ed. Somatostatin: basic and clinical status. New York, London: Plenum Press; 157-167.
8. Siperstein AE, Miller RA, Clark OH. 1992 Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue. World J Surg. 16:555-561.
9. Ain KB, Taylor KD. 1994 Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab. 78:1097-1102.
10. Demeure MJ, Damsky CH, Elfman F, Goretzki PE, Wong MG, Clark OH. 1992 Invasion by cultured human follicular thyroid cancer correlates with increased beta1 integrins and production of proteases. World J Surg. 16:770-776.
11. Ambiosi-Impiombato FS, Parks LAM, Coon HG. 1980 Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA. 77:3455-3459.
12. Hoelting Th, Zielke A, Siperstein AE, Clark OH, Duh QY. 1994 Transforming growth factor beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion in follicular and papillary thyroid cancer cell lines. J Clin Endocrinol Metab. 79:806-813.
13. Marbach P, Neufeld M, Pless J. 1985 Clinical applications of somatostatin analogs. Adv Exp Med Biol. 188:339-353.
14. Wood SM, Kraenzlin ME, Adrian TE, Bloom SR. 1985 Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue SMS 201-995: symptomatic and peptide responses. Gut. 26:438-447.
15. Andersen DK. 1989 Current diagnosis and management of Zollinger-Ellinson syndrome. Ann Surg. 210:685-691.
16. Gordon P. 1989 Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumor of the pituary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 110:35-48.
17. Klijn JGM, Hoff AM, Planting ASTh, et al. 1990 Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin-analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer. 62:627-634.
18. Wyninck D, Anderson JV, Williams SJ, Bloom SR. 1989 Resistence of metastatic pancreatic endocrine tumors after long term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf). 30:385-392.
19. Macaulay VM, Smith IE, Everard MJ, Teale JD, Reubi JC. 1991 Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer. 61:334-339.
20. Vermin Ph, Peyrat JP, Bonneterre J, Louchez MM, Harris AG, Demaille A. 1989 Effect of long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res. 9:153-159.
21. Qin Y, VanCauteren M, Osteaux M, Schally AV, Willems G. 1992 Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging. Cancer Res. 52:6025-6030.
22. Siegel RA, Tolcsvai L, Rudin M. 1988 Partial inhibition of transplanted Dunning rat prostate tumors with the long-acting somatostatin analogue Sandostatin (SMS 201-995). Cancer Res. 48:4651-4654.
23. Upp JR, Olson D, Poston GJ, Alexander RW, Townsend CM, Thompson JC. 1988 Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am Surg. 115:29-35.
24. Weckbecker G, Liu R, Tolcsvai L, Bruns C. 1992 Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 52:4973-4978.
25. Yasunami Y, Funakoshi A, Ryu S, et al. 1994 In vitro release of vasoactive intestinal polypeptide and pancreatic polypeptide from human VIPoma cells and its inhibition by somatostatin analogue (SMS 201-995). Surgery. 115:713-717.
26. Loos U, Escobar-Jimenez F, Raptis S, Birk J, Rothenbuchner G, Pfeiffer EF. 1977 Inhibition of TSH-induced release of triiodothyronine (T3) and thyroxine (T4) by somatostatin in man. Acta Endocrinol (Copenh). 208(Suppl):47-48.
27. Clark OH, Siperstein AE, Miller R, van Raavenswaay Claasen H. 1989 Receptors and receptor-transducing systems in normal and neoplastic human thyroid tissue. In: Goretzki PE, Roeher HD, eds. Frontiers in Hormone Research. Basel: Karger; vol 18:14-27.
28. Siperstein AE, Zeng QH, Gum ET, Levin KE, Clark OH. 1988 Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J Surg. 12:528-533.
29. Weber CJ, Marvin M, Krekun S, Koschitzky T, Karp F, Benson M. 1990 Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies. Surgery. 109:1065-1071.
30. Weber CJ, Merriam L, Koschitzky T, Karp F, Benson M, Forde K. 1989 Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surgery. 106:416-422.